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Purpose or Objective: To develop a model for grade 3 (G3) 
late rectal bleeding (LRB) after radical radiotherapy (RT) for 
prostate cancer, in a pooled population from two large 
prospective trials.  
 
Material and Methods: The trials included patients (pts) 
treated with a conventional fractionated 3DCRT at 66-80Gy. 
Planning data were available for all pts. G3 LRB was 
prospectively scored using the LENT/SOMA questionnaire, 
with a minimum follow-up of 36 months. Rectal dose-volume 
histograms were reduced to an Equivalent Uniform Dose 
(EUD) distribution calculated with volume-effect parameter, 
n, derived by 3 studies: n=0.018 (Defraene IJROBP2011), 
n=0.05 (Rancati RO2011) and n=0.06 (Rancati RO2004). EUD 
was inserted into a multivariable logistic (MVL) regression 
together with clinical and treatment features. Irradiation of 
seminal vesicles (SV), irradiation of pelvic nodes, hormonal 
therapy, hypertension, previous abdominal surgery (SURG), 
use of anticoagulants, diabetes, cardiovascular diseases and 
presence of acute toxicity were considered as potential dose-
modifying factors. Goodness of fit was evaluated with Hosmer 
Lemeshow test (HL), calibration through fitting slope, while 
the AUC was used for the discrimination power. 
 
Results: A total of 1337 pts were available: 708 from first 
trial and 669 from the second one. G3 LRB was scored in 95 
pts (7.1%): 62 and 33 in the first and second trial, 
respectively. EUD calculated with the volume parameter 
n=0.06 was the best dosimetric predictor for G3 LRB. A 4-
variable MVL model was fitted including EUD (OR=1.07 
p=0.02), SV (OR=4.75 p=0.01), SURG (OR=2.30 p=0.02) and 
cardiovascular disease (OR=1.42 p=0.18). This model had an 
AUC=0.63, a calibration slope=0.99 (R^2=0.89) and a p for 
HL=0.43.  
Figure 1 shows dose response relationship (model vs observed 
toxicity rates) as a function of SV irradiation, cardiovascular 
disease and abdominal surgery.  
Inclusion of acute toxicity (OR=2.34 p<0.001) slightly 








Conclusion: EUD with n=0.06 was predictive of G3 LRB in this 
pooled population, confirming the importance of sparing the 
rectum from high doses. Irradiation of seminal vesicles 
together with the presence of cardiovascular disease and 
previous abdominal surgery were relevant dose-modifying 
factors highly impacting the incidence of G3 LRB.  
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Purpose or Objective: In carbon ion radiotherapy (CIRT), 
mainly two calculation models are adopted to define relative 
biological effectiveness (RBE)-weighted doses (DRBE): the 
Japanese Kanai model and the Local Effect Model (LEM). 
Taken the Japanese longest-term clinical data as a reference, 
the use of a different RBE model, with no correction for the 
Gy (RBE) scale, leads to deviations in target absorbed dose 
(Dabs) with a potentially significant impact on tumor control 
probability. In this study we validate a conversion method 
linking the two DRBE systems, confirming DRBE prescription 
dose values adopted in our LEM-based protocols.  
 
Material and Methods: The NIRS beamline was simulated 
with a Monte Carlo (MC) code, according to design 
information about elements position, size and composition. 
Validation went through comparison between simulated and 
measured pristine and Spread Out Bragg Peaks, ridge filter 
based, in water. CT scan, structure set, plan and dose files of 
10 treatment fields delivered at NIRS were exported in DICOM 
format, for prostate (3.6 Gy (RBE) per 16 fractions), Head & 
Neck (4 Gy (RBE) per 16 fractions) and pancreas (4.6 Gy (RBE) 
per 12 fractions) patients. Patient specific passive system 
geometries (range shifter, MLC, compensator, collimator) 
were implemented, for each field, to simulate delivered Dabs 
distributions. The MC code was then interfaced with LEM to 
calculate DRBE resulting from the application of a different 
RBE model to NIRS physical dose. MC and TPS calculated Dabs 
and DRBE were compared in terms of dose profiles and target 
median dose. Patient CT and structure sets were also 
imported in a LEM-based commercial TPS where plans were 
optimized prescribing the non-converted and converted DRBE 
values, respectively. 
 
Results: The agreement between MC and measured depth 
dose profiles in water demonstrated beamline model 
accuracy. Patient dose distributions were correctly 
reproduced by MC in the target region, with an overall target 
median dose difference < 2%. MC median DRBE resulted 16% 
higher than NIRS reference, for the lower prostate dose level, 
